The drug most often at the center of this “banned then brought back” conversation in dementia care is aducanumab, marketed as Aduhelm by Biogen. Approved by the FDA in June 2021 through its controversial accelerated approval pathway, aducanumab became the first drug approved to target amyloid plaques in the brain — a hallmark of Alzheimer’s disease. But the approval was almost immediately met with backlash from the scientific community, insurance refusals from Medicare, and eventually Biogen’s own decision to pull the drug from the market in early 2024. Now, with the broader class of anti-amyloid therapies gaining ground through drugs like lecanemab (Leqembi), the debate over aducanumab’s legacy and whether it could ever return in some form continues to linger in neurology circles.
The story of aducanumab is not just about one drug. It is a case study in how regulatory shortcuts, commercial pressure, and genuine desperation among patients and families collide in the world of dementia treatment. Its FDA advisory committee actually voted against approval, and several members resigned in protest when the agency approved it anyway. For caregivers and families navigating Alzheimer’s, this history matters because it shapes how doctors approach every new dementia drug that reaches the market. This article covers why aducanumab was pulled, what it means for the current generation of anti-amyloid treatments, the real risks involved, and why your neurologist may be cautious even about drugs that are currently available.
Table of Contents
- Why Was the Alzheimer’s Drug Aducanumab Banned and Then Brought Back?
- The Real Risks of Anti-Amyloid Therapies and What Patients Should Know
- How Lecanemab and Donanemab Changed the Conversation After Aducanumab
- Questions to Ask Your Doctor Before Starting an Anti-Amyloid Drug
- Why Many Neurologists Remain Skeptical Despite FDA Approvals
- What This Means for Caregivers Managing Expectations
- Where Dementia Drug Development Goes From Here
- Conclusion
- Frequently Asked Questions
Why Was the Alzheimer’s Drug Aducanumab Banned and Then Brought Back?
Aducanumab was not banned in the traditional regulatory sense — it was not yanked for causing mass harm the way Vioxx was pulled from shelves. What happened was more complicated. Biogen halted two major Phase 3 clinical trials in 2019 after an independent data monitoring committee concluded the drug was unlikely to show benefit. Then, in a move that stunned researchers, Biogen reanalyzed a subset of data from one of those trials and claimed that patients who received the highest dose did show modest slowing of cognitive decline. The FDA worked closely with Biogen — critics said too closely — and granted accelerated approval in 2021 based on the drug’s ability to clear amyloid plaques, not on definitive proof that patients actually got better. The backlash was swift. Three members of the FDA’s own advisory committee resigned.
The European Medicines Agency refused to approve aducanumab. Medicare issued an extraordinary coverage restriction, agreeing to pay for the drug only if patients were enrolled in approved clinical trials — essentially limiting real-world access to almost nobody. Biogen initially priced the drug at $56,000 per year, later cutting it roughly in half, but uptake remained negligible. By January 2024, Biogen announced it would discontinue aducanumab to focus resources on other pipeline drugs. The “brought back” framing is less about aducanumab itself returning to pharmacy shelves and more about the entire anti-amyloid approach being resurrected through successor drugs like lecanemab, which received its own traditional FDA approval in 2023 after showing statistically significant (if modest) clinical benefit. Doctors remain cautious because the aducanumab saga exposed how thin the line can be between a breakthrough and a false hope. The clinical benefit of amyloid-clearing drugs, even the ones that did meet their endpoints, is measured in small fractions of a point on cognitive scales — improvements that many clinicians struggle to distinguish from noise in a real-world clinical setting.
The Real Risks of Anti-Amyloid Therapies and What Patients Should Know
The most significant safety concern with aducanumab and its successors is a set of side effects collectively known as amyloid-related imaging abnormalities, or ARIA. These show up on MRI scans as either brain swelling (ARIA-E) or tiny brain bleeds (ARIA-H). In aducanumab’s clinical trials, roughly 40 percent of patients receiving the higher dose experienced ARIA, though many cases were asymptomatic and detected only through routine monitoring scans. However, some patients experienced headaches, confusion, dizziness, and in rare cases, serious or life-threatening events. The risk is not evenly distributed. Carriers of the APOE4 gene variant — which is also one of the strongest genetic risk factors for Alzheimer’s itself — face substantially higher rates of ARIA.
This creates an uncomfortable paradox: the people most genetically predisposed to Alzheimer’s are also the ones most likely to experience dangerous side effects from the drugs designed to treat it. Genetic testing for APOE4 status has become a standard part of the screening process before prescribing anti-amyloid infusions, but the conversation around what to do when a patient is APOE4 homozygous (carrying two copies) remains difficult. If your loved one is being evaluated for one of these treatments, ask specifically about APOE4 testing and what the results mean for their individual risk profile. The monitoring burden is also substantial. Patients on these drugs typically require regular MRI scans — often monthly in the early months of treatment — to watch for ARIA. For elderly patients with dementia, the logistics of frequent imaging appointments, the potential for sedation, and the anxiety of repeated scans can be a significant quality-of-life consideration that does not always get enough weight in the prescribing conversation.
How Lecanemab and Donanemab Changed the Conversation After Aducanumab
Lecanemab, sold as Leqembi by Eisai and Biogen, arrived with something aducanumab never convincingly delivered: a completed Phase 3 trial showing a statistically significant slowing of cognitive decline. The Clarity AD trial demonstrated a 27 percent slowing of decline on a clinical dementia rating scale over 18 months compared to placebo. That number sounds meaningful in a press release, but in practice, it translated to a difference of about half a point on an 18-point scale. Whether patients or families could perceive this difference in daily life became a genuine scientific debate.
Donanemab, developed by Eli Lilly under the brand name Kisunla, followed a similar trajectory and received FDA approval in 2024. Its trial showed a roughly 35 percent slowing of decline in patients with intermediate levels of tau pathology, and Lilly positioned the drug with a notable twist: a treatment-stopping approach, where patients could discontinue infusions once their amyloid levels dropped below a certain threshold. This was a direct response to concerns about indefinite treatment with expensive IV infusions. For families dealing with an Alzheimer’s diagnosis today, the practical landscape looks like this: there are now FDA-approved drugs that target the underlying biology of the disease, but their benefits are modest, their risks are real, and access depends heavily on insurance coverage, proximity to infusion centers, and the willingness of a neurologist to prescribe them. In rural areas or under-resourced health systems, these treatments may be effectively unavailable despite being technically on the market.
Questions to Ask Your Doctor Before Starting an Anti-Amyloid Drug
The first and most important question is deceptively simple: is my loved one actually a candidate? Anti-amyloid drugs are approved for early-stage Alzheimer’s disease with confirmed amyloid pathology. This means a patient must undergo either a PET scan or a lumbar puncture to confirm the presence of amyloid plaques. Patients with moderate-to-severe dementia were excluded from clinical trials and are generally not considered appropriate candidates. If a doctor is willing to prescribe these drugs for advanced dementia, that should raise a red flag. Second, ask about the realistic benefit versus the treatment burden. The infusions for lecanemab, for example, are administered every two weeks intravenously. Each session may take an hour or more, not including travel time and the monitoring appointments.
For a patient with early Alzheimer’s who is still living independently, this schedule might be manageable. For a patient who relies on a caregiver for transportation and daily activities, the toll of biweekly infusions can be considerable. Compare this with the expected benefit: a modest slowing of decline that may or may not be perceptible to the patient or family over 18 months of treatment. Third, ask about cost and coverage. As of recent reports, the annual cost of lecanemab has been in the range of $26,500, though out-of-pocket costs vary widely depending on insurance. Medicare coverage has expanded beyond the narrow restrictions initially placed on aducanumab, but coverage details, copay requirements, and prior authorization processes differ by plan. Do not assume that FDA approval means straightforward access.
Why Many Neurologists Remain Skeptical Despite FDA Approvals
The caution among clinicians is not stubbornness or ignorance of new science. It is rooted in a genuine interpretive disagreement about what the trial data actually mean for patients. A 27 percent relative reduction in cognitive decline sounds significant, but when the absolute difference is fractions of a point on a rating scale, many experienced neurologists question whether the benefit justifies the risks, costs, and logistical demands of treatment. This is not a fringe position — it is a mainstream concern expressed in peer-reviewed editorials and at major neurology conferences. There is also the shadow of aducanumab’s approval process. The FDA’s decision to approve a drug that its own advisory committee rejected — and the subsequent investigation by the Office of the Inspector General into the unusually close collaboration between the FDA and Biogen — damaged trust in the regulatory process itself.
Some physicians worry that the accelerated approval pathway, originally designed for drugs treating life-threatening conditions with unmet need, has been stretched to cover drugs with marginal benefit. When a new anti-amyloid drug reaches the market, doctors who lived through the aducanumab controversy are understandably more skeptical than they might otherwise be. It is worth noting that skepticism is not the same as nihilism. Many cautious neurologists still discuss these drugs with appropriate patients and support informed decision-making. The caution manifests as thorough screening, honest conversations about expected benefits, and a reluctance to oversell what these drugs can do. If your doctor seems hesitant, it may actually be a sign that they are taking the decision seriously rather than dismissing new options.
What This Means for Caregivers Managing Expectations
For families, the emotional weight of these drugs cannot be overstated. After decades of failed Alzheimer’s drug trials, having any approved treatment that targets the disease mechanism feels like a lifeline. But caregivers need to understand that “slowing decline” is not the same as “stopping decline” or “getting better.” A patient on lecanemab or donanemab will still progress.
The hope is that they progress more slowly, potentially preserving months of functional ability that would otherwise be lost. For some families, those months are priceless. For others, the burden of treatment may not be worth the incremental benefit. One practical example: a caregiver whose spouse was enrolled in a clinical trial for one of these drugs described the experience as “six months of logistical chaos for a change I couldn’t honestly see.” That is not a universal experience, but it is an honest one, and it reflects a reality that clinical trial endpoints do not always capture.
Where Dementia Drug Development Goes From Here
The next frontier is not necessarily a bigger or better amyloid-clearing antibody. Researchers are increasingly focused on combination approaches — targeting amyloid alongside tau, neuroinflammation, or synaptic function. Several anti-tau therapies are in clinical trials as of recent reports, and there is growing interest in drugs that address neuroinflammation pathways, which may play a role in neurodegeneration independent of amyloid burden.
The aducanumab story, for all its controversy, did accomplish one thing: it proved that the amyloid hypothesis is at least partially actionable. You can clear amyloid from living human brains. Whether that is sufficient to meaningfully help patients remains the billion-dollar question, and the honest answer is that we are still finding out. For families dealing with dementia today, the best posture is cautious optimism — stay informed, ask hard questions, and do not let desperation override careful medical judgment.
Conclusion
The saga of aducanumab — from failed trials to controversial approval to market withdrawal — is a cautionary tale about the distance between scientific promise and clinical reality. The anti-amyloid drugs that followed, lecanemab and donanemab, represent genuine scientific progress, but their benefits remain modest and their risks nontrivial. For patients and caregivers, the most important takeaway is that these drugs are tools, not cures, and they are appropriate only for a specific subset of patients with early-stage, amyloid-confirmed Alzheimer’s disease.
If you or a loved one is considering one of these treatments, start with a thorough evaluation that includes amyloid confirmation and APOE4 testing. Have an honest conversation with your neurologist about what realistic benefit looks like, and weigh that against the treatment burden. The era of disease-modifying Alzheimer’s drugs has arrived, but it has arrived with caveats — and the doctors who take those caveats seriously are the ones you want in your corner.
Frequently Asked Questions
Is aducanumab still available for patients?
As of Biogen’s announcement in early 2024, aducanumab (Aduhelm) was being discontinued. Patients who were receiving it through clinical trials may have transitioned to other treatments, but new prescriptions are generally not being written.
What is the difference between lecanemab and donanemab?
Both are anti-amyloid antibodies, but they target slightly different forms of amyloid. Lecanemab targets amyloid protofibrils, while donanemab targets a modified form of deposited amyloid plaque. Donanemab’s trial also introduced a treatment-stopping approach once amyloid levels dropped sufficiently, whereas lecanemab is designed as an ongoing infusion therapy.
Can these drugs reverse Alzheimer’s symptoms?
No. Current anti-amyloid drugs are designed to slow the rate of cognitive decline, not reverse it. Patients and families should not expect improvement in symptoms — the goal is to preserve current function for longer than would occur without treatment.
Who should NOT take these drugs?
Patients with moderate-to-severe Alzheimer’s, those without confirmed amyloid pathology, and individuals at high risk for ARIA (particularly APOE4 homozygotes) may not be appropriate candidates. Blood-thinning medications can also increase the risk of brain bleeds associated with ARIA.
Does Medicare cover these treatments?
Medicare coverage for lecanemab was broadened after its traditional FDA approval, but coverage details and out-of-pocket costs vary. Check with your specific Medicare plan and the prescribing facility for current coverage information.
Are there non-drug alternatives for slowing Alzheimer’s progression?
Research consistently supports physical exercise, cognitive engagement, social activity, cardiovascular health management, and adequate sleep as factors that may influence the rate of cognitive decline. These approaches carry no ARIA risk and benefit overall health regardless of their effect on dementia specifically.
